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The taxanes paclitaxel and docetaxel show good activity in the management of advanced ovarian cancer when used in conjunction
with platinum agents. Accumulating evidence from clinical studies, particularly the latest results from the phase III comparative
SCOTROC study, indicates that the two drugs confer similar rates of tumour response and survival in women with this condition.
However, it is clear that paclitaxel and docetaxel differ in their tolerability profiles and in other respects, and cannot be regarded as
directly equivalent drugs. In particular, paclitaxel is associated with significant neurotoxicity; peripheral neuropathy has also been
reported with docetaxel, but to a lesser extent. Neutropenia appears more prevalent with docetaxel than with paclitaxel, although
clinical trial data show that this adverse effect is manageable and need not compromise dose delivery. Docetaxel is also associated
with potential benefits accruing from shorter infusion times and lack of need for premedication with intravenous histamine H1 and H2
antagonists. Emerging quality of life data are expected to shed further light on the overall benefit of chemotherapy in women with
advanced ovarian cancer in general, and on taxane platinum combinations in particular.
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Despite advances in diagnostic techniques and therapy, cancer of
the ovary kills more women than any other tumour of the
reproductive system and therefore remains the gynaecological
malignancy of greatest concern in industrialised countries
(National Library of Medicine, 1994; Dunton, 1997). Only a
minority of patients present early enough for complete removal of
the tumour to be successful, and chemotherapy is therefore the
mainstay of treatment for the majority of women with ovarian
cancer (Lister-Sharp et al, 2000) (80% of patients presented with
advanced stage). Two classes of cytotoxic agents, the platinums
and the taxanes, have emerged as key components of chemother-
apy regimens for advanced disease (Kaye, 2001).
The place of paclitaxel in the treatment of advanced ovarian
cancer is well established, but a newer member of the taxane
group, docetaxel, has been developed more recently. Docetaxel
differs from paclitaxel in a number of respects and represents an
alternative taxane with considerable promise and potential
tolerability advantages in the management of ovarian cancer
(Guastalla et al, 1999; Vasey et al, 1999; Gorbounova et al, 2000;
Vasey et al, 2001; Vasey and the Scottish Gynaecological Cancer
Trials Group, 2001). In cases where different drugs show similar
survival benefit in advanced malignant disease, issues relating to
toxicity and quality of life (QoL) become increasingly important.
Current data suggest that the taxanes paclitaxel and docetaxel
have similar efficacy, but regimens based on either of these two
drugs have shown potentially important differences in their
toxicity profiles. As it is always important to balance risks and
benefits when setting out treatment plans for individual patients,
knowledge of the tolerability differences between the taxanes
available is clearly necessary for informed treatment decisions to
be made. As part of this debate, this article reviews the toxicity
profiles of each taxane and discusses QoL issues affecting patients
with ovarian cancer.
Clinical benefit of taxane-based chemotherapy
The clinical benefit in terms of median overall and progression-
free survival of combining paclitaxel rather than an alkylating
agent with a platinum compound in stage III–IV (McGuire et al,
1996) or stage IIb–IV (Piccart et al, 2000) disease has been shown
in first-line studies in a total of 1057 women. Further data from
three major studies in a total of 1798 patients show enhancement
of this benefit via improved overall tolerability when cisplatin is
replaced by carboplatin (Neijt et al, 2000; du Bois et al, 2003; Ozols
et al, 2003).
Concerns over neurotoxicity when paclitaxel and cisplatin are
used together have led to evaluation of the combination of
docetaxel with cisplatin: three studies of this type of first-line
therapy showed encouraging overall clinical response rates of
69–74% (Guastalla et al, 1999; Vasey et al, 1999; Gorbounova
et al, 2000) Neurotoxicity of any grade was reported in 16 and
26% of patients in two of the studies (Guastalla et al, 1999;
Gorbounova et al, 2000), and 23% of patients in the other trial
experienced neurotoxicity of severity greater than grade 1 (Vasey
et al, 1999).
In addition, the promise of similar antitumour activity with
reduced toxicity (notably neurotoxicity, ototoxicity, nephrotoxi-
city and gastrointestinal toxicity) when carboplatin is used in place *Correspondence: Dr JP Guastalla III; E-mail: guastall@lyon.fnclcc.fr
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explore combinations of docetaxel and carboplatin. A feasibility
study of first-line therapy in 139 patients treated with a range of
combination dosages of carboplatin plus docetaxel yielded an
overall response rate of 66% and median progression-free survival
of 16.6 months, with extremely low levels of neurotoxicity (Vasey
et al, 2001). The efficacy and safety of 3-weekly docetaxel 70–
75mgm
 2 with carboplatin to achieve an area under the plasma
drug concentration vs time curve (AUC) of 5–6mgml
 1min
 1
have subsequently been confirmed in a series of three phase II
studies in a total of 66 patients (Meyer et al, 1999; Kolevska et al,
2001; Vorobiof et al (2003)). In addition, preliminary comparative
data from the Scottish Gynaecological Cancer Trials Group’s phase
III SCOTROC study in 1077 chemotherapy-naı ¨ve patients have
indicated that paclitaxel and docetaxel have comparable efficacy
when either is combined with carboplatin, but that there are
significant differences in the tolerability characteristics of the two
regimens (Vasey and the Scottish Gynaecological Cancer Trials
Group, 2001).
DOSAGE AND ADMINISTRATION ISSUES
Dosage and schedule
Both docetaxel and paclitaxel are usually administered once every
3 weeks. Most patients with ovarian cancer receive paclitaxel as a
3-h infusion, whereas docetaxel is given over 1h. This shortened
infusion time suggests a potential advantage in terms of patient
convenience and other factors such as clinic time and resources for
docetaxel.
Although the majority of clinical trials involving the taxanes
have involved 3-weekly administration, weekly schedules have also
been investigated. There is an underlying pharmacokinetic
rationale for such regimens in that they may mimic continuous
infusions and thereby increase cellular drug exposure (Boehnke
Michaud et al, 2000); weekly regimens have also been linked with
reduced levels of myelotoxicity and subsequent potential for
optimisation of dose intensity. Phase I data obtained in 18
previously treated patients with relapsed advanced ovarian cancer
showed attainment of 90.75% of planned dose intensity with
weekly escalating doses of paclitaxel (40–100mgm
 2) (Fennelly
et al, 1997). A 30% partial response rate was noted in 13 assessable
patients, and there was no evidence of cumulative myelosuppres-
sion.
Weekly infusions of docetaxel were associated with minimal
myelotoxicity in women with advanced refractory ovarian cancer
(Hainsworth et al, 1998). Myelosuppression was not dose limiting
from 20–52mgm
 2 weekly in 35 evaluable patients. Grade III
leucopenia was noted in 14% of the patients, and there were no
reports of grade IV leucopenia or grade III or IV thrombocyto-
penia or anaemia.
A phase II trial from Japan has evaluated weekly paclitaxel
80mgm
 2 plus carboplatin to AUC 1.5–2.0 in 17 patients, 14 of
whom had advanced ovarian cancer (Kurihara et al, 2001). The
overall response rate of 64.7% included patients who had received
previous chemotherapy. Neutropenia of severity greater than grade
III was reported in 29.4% of patients, and QoL as demonstrated by
the European Organization for Research and Therapy of Cancer
(EORTC) core QLQ-C30 questionnaire suggested that weekly
chemotherapy might be better tolerated overall than a 3-weekly
schedule. In addition, Markman et al (2002) have recently assessed
the effect of increasing the dose intensity of paclitaxel by giving
80mgm
 2 each week to 53 patients who had failed to respond to a
conventional 3-weekly regimen consisting of paclitaxel and a
platinum agent. An overall objective response rate of 25% was
achieved in this phase II study, and peripheral neuropathy of grade
2 severity or greater was observed in seven patients (13%) of whom
four withdrew from the study.
Premedication guidelines
Patients receiving taxane therapy require premedication to
minimise the risk of hypersensitivity reactions. However, the
premedication guidelines recommended for paclitaxel and doc-
etaxel are markedly different (Boehnke Michaud et al, 2000). As
indicated in Table 1, patients who receive paclitaxel require both
intravenous histamine H1 and H2 antagonists in addition to oral
corticosteroids before 1-, 3- or 24-h infusions, although there is
some evidence that premedication is not needed before prolonged
infusions (those exceeding 96h). By contrast, the premedication
regimen recommended for patients receiving docetaxel consists of
3 days’ oral dexamethasone (8mg twice daily).
Corticosteroid therapy is used in part to prevent hypersensitiv-
ity reactions, but major aims are to delay the onset and decrease
the severity of fluid retention, and to decrease the frequency and
severity of skin and nail changes (Boehnke Michaud et al, 2000). A
5-day premedication was originally recommended for patients
being treated with docetaxel, but this was subsequently reduced to
3 days after the latter regimen was shown to be associated with
similar rates of fluid retention and less mucositis and infection.
ADVERSE EVENTS
Haematological toxicity
The dose-limiting toxicity of both docetaxel and paclitaxel is
neutropenia or, more specifically, febrile neutropenia (Boehnke
Michaud et al, 2000). According to collated data from single-agent
clinical trials (Aventis Pharmaceuticals Products Inc., 2002),
docetaxel 100mgm
 2 over 1h every 3 weeks is associated with
severe neutropenia (o500cellsmm
 3) in 75.4% of patients; the
corresponding rate with paclitaxel (135–300mgm
 2 over 24h) is
reported to be 52% (Mead Johnson Oncology Products, 2000). At a
dose of 250mgm
 2 over 24h, paclitaxel is associated with an
incidence of febrile neutropenia of 16–36%, with other incidences
being reported with other infusion durations (Boehnke Michaud
Table 1 Premedication guidelines for the taxanes
Paclitaxel Docetaxel
Drugs 1h 3h 24h 96h 1h
Histamine H1 antagonist (diphenhydramine 50mg) IV prior IV prior IV prior None None
Histamine H2 antagonist (cimetidine 300mg, ranitidine
50mg, famotidine 20mg)
IV prior IV prior IV prior None None
Dexamethasone 20mg p.o.
12 and 6h prior
20mg p.o.
12 and 6h prior
20mg p.o.
12 and 6h prior
None 8mg
twice daily 3 days
starting 24h prior
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docetaxel 100mgm
 2 every 3 weeks is reported to be 11% in
patients with normal liver function (Aventis Pharmaceuticals
Products Inc., 2002).
Neutropenia is not cumulative with either taxane, and leucocyte
counts typically recover 21 days after administration in nearly all
patients (Pazdur et al, 1993; Fulton and Spencer, 1996). In almost
all patients receiving paclitaxel, white cell counts begin to fall 5–7
days after administration, with a nadir being reached between day
7 and day 14. This phenomenon is seen earlier in docetaxel
recipients: white cell counts start to fall 4–6 days after
administration, and a nadir is reached between day 6 and day 8.
The severity of neutropenia can be minimised by the
prophylactic addition of colony-stimulating factor to the first
course of taxane chemotherapy, or when necessary throughout the
treatment cycle (Boehnke Michaud et al, 2000). Clinical practice in
this respect varies, with decisions on the use of colony-stimulating
factor being based on the regimen being used and types of patient
involved, although guidelines (e.g. from the American Society of
Clinical Oncology (Ozer et al, 2000) and European Society of
Medical Oncology (ESMO, 2001)) are also available.
Grade IV neutropenia was reported in 75% of 139 patients with
stage Ic–IV ovarian cancer who received 3-weekly docetaxel 60–
85mgm
 2 plus carboplatin to AUC 5 or 6 in the recent dose-
finding study described earlier in this review (Vasey et al, 2001).
Preliminary results from the first phase III comparison of
docetaxel (75mgm
 2 over 1h) plus carboplatin to AUC 5 with
paclitaxel (175mgm
 2 over 3h) plus carboplatin (the Scottish
Randomised Trial in Ovarian Cancer, or SCOTROC, study in 1077
patients with grade Ic–IV ovarian carcinoma) supported these
findings by showing a significant difference between the two
treatments in tolerability profiles (Vasey and the Scottish
Gynaecological Cancer Trials Group, 2001). A higher proportion
of patients in the docetaxel arm than in the paclitaxel arm
experienced grade IV neutropenia (80 vs 55%), although this was
reported by the authors not to have compromised dose delivery or
patient safety. As already discussed, guidelines are in place to aid
clinicians in the use of colony-stimulating factors in patients likely
to be at risk of myelosuppression, and appropriate treatment of
this type would be expected to minimise the incidence and severity
of neutropenia in patients receiving docetaxel with carboplatin in
future studies.
Of additional interest in this respect are the observations
(reported earlier) of Hainsworth et al (1998), who showed no grade
IV leucopenia in their study of weekly docetaxel in 35 patients with
advanced ovarian cancer. This suggests that weekly schedules of
docetaxel may offer a clinical alternative for the minimisation of
myelosuppression.
Neurotoxicity
Paclitaxel use is associated with neuropathy that is predominantly
sensory. This adverse effect appears to be dose-related, and is
usually observed 24–72h after single doses exceeding 250mgm
 2
or after multiple doses of 135–200mgm
 2. Patients who have
received previous treatment with neurotoxic drugs appear in
particular to be predisposed to this reaction. The neuropathy
typically manifests initially as a burning or tingling sensation in
the glove and stocking areas, and can progress to motor weakness
with continued administration of the drug (Pazdur et al, 1993).
The severity and frequency of peripheral neuropathy with
paclitaxel may be related to infusion times in addition to dose,
with more rapid infusions being associated with higher incidences.
This is illustrated by results from two pivotal phase III studies that
established the superiority of 3-weekly cisplatin plus paclitaxel
over cisplatin plus cyclophosphamide in a total of 1057 evaluable
patients with advanced ovarian cancer. Cisplatin and cyclopho-
sphamide were given at the same dosages in both studies (75 and
750mgm
 2, respectively), but in one study a 24-h infusion of
paclitaxel 135mgm
 2 was given (McGuire et al, 1996), whereas a
3-h infusion of 175mgm
 2 was used in the other (Piccart et al,
2000). There was no significant difference between treatments in
incidence or severity of neuropathy in the 24-h infusion study
(grade III–IV neurological symptoms in 4% of patients in each
group); however, in the 3-h infusion study a marked neuropathic
effect occurred in 19% of patients receiving cisplatin–paclitaxel
compared with 1% of patients treated with cisplatin–cyclopho-
sphamide (Figure 1).
Concerns over the neurotoxicity of combinations of paclitaxel
with carboplatin have been raised by several authors. Three key
comparative trials of paclitaxel–cisplatin vs paclitaxel–carboplatin
— the Dutch–Danish trial (Neijt et al, 2000), the Gynecologic
Oncology Group (GOG) 158 study (Ozols et al, 2003) and the
Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) trial (du
Bois et al, 2003) —reported similar efficacy for both combination
regimens in patients with advanced ovarian cancer but less
neurotoxicity with carboplatin than cisplatin. Nevertheless, as
shown in Table 2, a noteworthy fraction of carboplatin recipients
were affected by this adverse effect in the Dutch–Danish and AGO
trials. According to the recent report of the GOG 158 trial (Ozols
et al, 2003), 28% of patients who received carboplatin with
paclitaxel (n¼400) compared with 31% in the cisplatin–paclitaxel
arm (n¼392) were affected by grade II–IV neurotoxicity.
Peripheral neuropathy and myalgia/arthralgia have also been
reported in patients receiving docetaxel, but to a lesser extent than
in those receiving paclitaxel; neurotoxicity is also generally not
dose limiting for docetaxel (Fulton and Spencer, 1996). Although
fewer data are available for docetaxel than for paclitaxel in ovarian
cancer, two studies of combination chemotherapy with docetaxel
(dosages ranged from 40–85mgm
 2 every 3 weeks) and
carboplatin (AUC 4–6) in a total of 189 patients with ovarian
and other carcinomas both showed incidences of peripheral
neuropathy (Markman et al, 2001) or grade II–III neurotoxicity
(Vasey et al, 2001) of only 6%.
Preliminary results from the SCOTROC study (Vasey and the
Scottish Gynaecological Cancer Trials Group, 2001) supported
these findings: grade II–III sensory neuropathy was reported in 10
and 28% of patients (Po0.001) in the docetaxel–carboplatin and
paclitaxel–carboplatin groups, respectively. Most recent results
(Vasey and the Scottish Gynaecological Cancer Trials Group, 2002)
are similar: patients in the docetaxel arm reported less tingling in
hands and feet and numbness in fingers and toes than those in the
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Figure 1 Neurosensory/neuromotor adverse events across all treat-
ment cycles in 675 assessable patients with stage IIb–IV ovarian cancer in a
phase III study (Piccart et al, 2000). Patients were randomly assigned to
receive (i) paclitaxel 175mgm
 2 over 3h followed by cisplatin 75mgm
 2
or (ii) cyclophosphamide 750mgm
 2 followed by cisplatin 75mgm
 2 for
six to nine cycles.
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10 (Po0.005) months after randomisation. Arthralgia and myalgia
were also reported significantly less frequently by docetaxel than
paclitaxel recipients (Figure 2). Note that these data were obtained
with the EORTC’s OV28 ovarian cancer module as described later
in this review.
Other adverse events
In general, proportions of patients experiencing grade III–IV
nonhaematological adverse events such as arthralgia, myalgia,
diarrhoea, hypersensitivity and fluid retention remain below 10%
when premedication is administered with the taxanes as recom-
mended (Boehnke Michaud et al, 2000; Kaye 2000; Vasey et al,
2001). Fluid retention syndrome appears to be confined to patients
receiving docetaxel, although mild peripheral oedema has been
reported with paclitaxel (Boehnke Michaud et al, 2000). The first
sign of fluid retention is weight gain: early treatment with diuretics
is effective in limiting the severity of the condition, which is most
likely to be of concern in patients with congestive heart failure or
other comorbid conditions (Boehnke Michaud et al, 2000).
As with the majority of chemotherapeutic agents, alopecia is
common with either docetaxel or paclitaxel, with the whole body
being affected approximately 10–14 days after the beginning of
therapy (Boehnke Michaud et al, 2000). Although this adverse
effect can have significant effects on body image, it does not pose
any clinical risk to the patient.
Quality of life
Since the definition over 50 years ago by the World Health
Organization of health as not only the absence of disease and
infirmity but also as the presence of physical, mental and social
well-being, QoL issues have assumed increasing prominence in
healthcare practice and research (Testa and Simonson, 1996).
Accordingly, the goals of chemotherapy in advanced cancer should
include improvement in QoL as well as increased duration of
survival. Quality of life is therefore assuming ever-greater
importance in the evaluation of cancer treatments.
Quality of life measurements and interpretation depend at least
in part on patient characteristics, including stage and extent of
disease, and on the type of treatment received, but there is general
agreement on the usefulness of QoL assessments in the compar-
ison of different therapies that confer similar survival in advanced
cancer (Pignata et al, 2001). Alternatively, a clinically superior
treatment may be so poorly tolerated that any survival advantage
gained may not be sufficient to offset losses in QoL.
QoL issues of special relevance in patients with gynaecological
(and therefore ovarian) cancer include limitations of sexual
activity, early menopause, chemotherapy-induced toxicity and
loss of body image (Pignata et al, 2001). Furthermore, it has been
shown that awareness of severe disease is more frequent among
women with ovarian cancer than among women with other types
of malignancy (Porzio et al, 1999). Most generic QoL tools do not
adequately capture disease-specific information or address treat-
ment-related issues relevant to women with ovarian cancer, but the
EORTC has recently developed an instrument specifically to deal
with this problem.
The EORTC OV28 module
The EORTC core QoL questionnaire QLQ-C30 was introduced in
the early 1990s as a psychometrically robust and cross-culturally
acceptable questionnaire designed to be applicable to a broad
spectrum of cancer patients, and is now in widespread use
worldwide. The development of OV28 as a QoL instrument for
patients with ovarian cancer follows the EORTC’s strategy of
supplementing the generic QLQ-C30 questionnaire with disease-
and/or treatment-specific modules to address issues of relevance to
particular patient groups (Cull et al, 2001).
The provisional module as described in 2001 (Cull et al, 2001)
has 28 items assessing abdominal symptoms, peripheral neuro-
pathy, other chemotherapy-related side effects, hormonal symp-
toms, body image, attitude to disease and treatment and sexual
functioning. The first 24 items of the module (items 31–54 as
added to QLQ-C30), excluding questions on sexual functioning,
have been assessed in a scaling analysis carried out with data from
277 patients participating in the SCOTROC trial (Cull et al, 2001;
Vasey and the Scottish Gynaecological Cancer Trials Group, 2001,
2002). The mean scale scores were found to discriminate between
Table 2 Neurotoxicities reported in the Dutch–Danish
a and AGO
b studies of paclitaxel–cisplatin vs paclitaxel–carboplatin
Dutch–Danish (n¼208) AGO (n¼772) GOG 158 (n¼792)
Treatment arm
Grade II
neurotoxicity (%)
Grade III
neurotoxicity (%)
Grade III–IV peripheral
neuropathy (%)
Grade III
neurotoxicity (%)
Paclitaxel+cisplatin 26 6 14 8
Paclitaxel+carboplatin 17 3 7 7
aPaclitaxel 175mgm
 2 over 3h+either cisplatin 75mgm
–2 or carboplatin to AUC 5 (Neijt et al, 2000).
bPaclitaxel 185mgm
 2 over 3h+either cisplatin 75mgm
 2 or
carboplatin to AUC 6 (du Bois et al, 2003).
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Figure 2 Incidences of arthralgic/myalgic symptoms and weakness in
arms and legs reported in the multicentre phase III SCOTROC study of 3-
weekly carboplatin to AUC 5 with either paclitaxel 175mgm
 2 infused
over 3h or docetaxel 75mgm
 2 over 1h (Vasey and the Scottish
Gynaecological Cancer Trials Group, 2002). Chemotherapy was given for
up to six cycles as first-line treatment in women with grade Ic–IV ovarian
cancer. Patient numbers denote those available for assessment of each
adverse event shown.
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OV28 module was indicated as a promising tool for the assessment
of QoL of women with ovarian cancer. Emerging data from the
SCOTROC study (Vasey and the Scottish Gynaecological Cancer
Trials Group, 2002) show further the utility of OV28, particularly
in terms of effect of chemotherapy on well-being (see neurotoxicity
discussion earlier and Figure 2).
Quality of life has been investigated in patients with ovarian
cancer in various studies, some of which are summarized in
Table 3. A review of 20 papers, 10 of which were treatment-related
QoL assessments and 10 of which dealt with other issues including
psychometric evaluation, was published in the mid-1990s, and
concluded that the Rotterdam Symptom Checklist and EORTC
QLQ-C30 were the most appropriate instruments for use in
patients with ovarian cancer at that time (Montazeri et al, 1996).
However, this review was published before the development and
introduction of the OV28 module. Thus, despite the inability of
any instrument available to date to measure chemotherapy-related
QoL directly, the lack of any comparative QoL data specific to
patients receiving taxane therapy has resulted in considerable
interest in the publication of the final analyses of the SCOTROC
results.
Psychological distress and QoL in ovarian cancer patients
As indicated in Table 3, studies are available to show the effect of
psychological distress on patients with ovarian cancer. Kornblith
et al (1995) examined physical, social and psychological well-being
with a variety of instruments in 151 ovarian cancer patients (see
Table 3), and reported significant psychological distress (expressed
as 1.5 s.d. above a predetermined nationwide community sample
standard in Mental Health Inventory psychological distress scores)
in one-third of patients at study entry. Interestingly, but perhaps
not surprisingly, impaired physical functioning was the most
important predictor of heightened psychological distress.
A subsequent study evaluated psychological distress and QoL
and examined the relationship between these problems and health
and demographic variables in 246 patients with ovarian cancer
who completed questionnaires (Bodurka-Bevers et al, 2000).
Clinically significant depression and anxiety, assessed with the
Center for Epidemiologic Studies Depression scale (CES-D) and
State Anxiety subscale of the Spielberger State-Trait Anxiety
Inventory, were found to be more prevalent than had been
expected. Clinical depression was shown in 21% of patients, while
29% scored above the 75th percentile for anxiety. Further studies
of screening and treatment of psychological distress were
recommended to improve QoL outcomes in women with ovarian
cancer.
Of particular interest in the context of this review is a recent
study involving a chart review of 60 women with ovarian cancer
undergoing chemotherapy with platinum agents (Lakusta et al,
2001). Analysis of EORTC QLQ-C30 questionnaire responses from
these patients was used to relate biomedical variables to QoL
outcomes and to compare patients receiving cisplatin as first-line
therapy with those receiving palliative carboplatin for recurrent
disease. Women receiving first-line cisplatin reported more
appetite disturbance, diarrhoea and nausea than those on palliative
carboplatin. Most notably, QoL declined over time in the newly
diagnosed patients, whereas improvements were noted in those
with recurrent disease, and lower QoL was found to predict death
within 12 months of starting treatment. It was concluded on the
basis of these results that the EORTC QLQ-C30 instrument can be
used to test clinical assumptions and to influence treatment
programmes in women with ovarian cancer undergoing che-
Table 3 Examples of QoL assessments undertaken in studies in women with advanced (unless stated otherwise) ovarian cancer
Study
Drugs given
(no. of patients) QoL instruments Summary of findings
Bodurka-Bevers
et al (2000)
Various (246 – 74% with
advanced disease)
Assessment of physical, functional,
emotional and social/family well-
being. CES-D, State Anxiety
subscale of Spielberger State-Trait
Anxiety Inventory, Zubrod scores
Performance status related to depression, anxiety and
QoL problems, except for social well-being
Ersek et al (1997) Various (study in 152
survivors – all disease
stages)
QoL – Cancer Survivors tool QoL moderately high despite negative findings related
to facets of the illness and treatment experiences.
Qualitative results reflect complexity of the cancer
experience
Kornblith et al
(1995)
Various (151 – 86% with
advanced disease)
Memorial Pain Assessment Card;
Memorial Symptom Assessment
Scale; MHI; FLIC; KPS
QoL assessed at 3-month intervals. Impaired physical
functioning (FLIC) most important predictor of
psychological distress (MHI) at baseline. Significant
differences in all QoL scales between patients with
KPSp80 and those with KPSX90. Need for improved
and more frequent assessment of psychological status
stressed
Lakusta et al (2001) First-line cisplatin and
second-line carboplatin
(chart review of 60
patients)
EORTC QLQ-C30 Less impact of carboplatin than cisplatin on QoL.
Improved QoL over time in patients with recurrent
disease supports palliative use of carboplatin
Schink et al (2001) Paclitaxel+carboplatin (59) FACT-OC Improvement in QoL and physical well-being scores
during this study of outpatient treatment
Willemse et al
(1990)
Cyclophosphamide+
doxorubicin+cisplatin (68)
TWiST Correction of progression-free survival with TWiST
suggested as being suitable for comparing effect of
differing chemotherapy schedules on QoL
Willemse et al
(1992)
Carboplatin+
cyclophosphamide (76)
TWiST QoL as measured by TWiST significantly better than
cyclophosphamide–doxorubicin–cisplatin (CAP-5) by
comparison with historical control group (n¼65)
Abbreviations: CES-D¼Center for Epidemiologic Studies–Depression scale; EORTC QLQ-C30¼European Organization for the Research and Treatment of Cancer Quality of
Life Questionnaire core items; FACT-OC¼Functional Assessment of Cancer Therapy – Ovarian Cancer scale; FLIC¼Functional Living Index – Cancer; KPS¼Karnofsky
Performance Scale; MHI¼Mental Health Inventory; QoL¼quality of life; TWiST¼time without symptoms of disease or treatment.
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carboplatin as a palliative agent in advanced disease. They also
indicate the potential utility of structured QoL assessments before
clinic appointments as a means of improving overall patient care.
CONCLUSIONS
Despite similarities in chemical structure and mode of action,
docetaxel and paclitaxel cannot be regarded as having the same
properties when used clinically. Study results have shown that the
substitution of docetaxel for paclitaxel in a platinum-based doublet
does not compromise efficacy, but that such substitution may
confer benefits in terms of convenience to patients and toxicity.
The reduced infusion time generally used with docetaxel (1 rather
than 3h), together with the need for premedication with oral
dexamethasone only, is likely to be more convenient and to reduce
the stress placed on patients by their treatment relative to
paclitaxel. Docetaxel—carboplatin has also been associated with
reduced frequency and severity of neurotoxicity relative to
paclitaxel/carboplatin in clinical studies in patients with ovarian
cancer. Higher incidences of neutropenia have been reported in
patients receiving the docetaxel combination, but this is reported
to be easily managed and is not associated with increases in rates
of treatment discontinuation or death.
There are currently few data relevant to QoL in patients
receiving taxane–platinum combinations for ovarian cancer, and
QoL instruments cannot measure directly chemotherapy-related
adverse effects. Nevertheless, the need for meaningful QoL
assessments and the subsequent implications for treatment plans
have become clear over the past decade, and results gained with
the instruments available in comparative trials are awaited with
interest. Familiarity of clinicians with differences between regi-
mens in terms of toxicity, dosage and administration and QoL
issues as data emerge and accumulate will assist in the
optimisation of treatment decisions in patients with ovarian
cancer.
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